Exogenous and endogenous markers of tumour oxygenation status: Definitive markers of tumour hypoxia?

Advances in Experimental Medicine and Biology

Volumn 566, Issue , 2005, Pages 285-294

  Williams, Kaye J ^a   Parker, Catriona A ^a   Stratford, Ian J ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 NITRO 1H IMIDAZOL 1 YL) N (2,2,3,3,3 PENTAFLUOROPROPYL)ACETAMIDE; BIOLOGICAL MARKER; CARBOGEN; CARBONATE DEHYDRATASE IX; CELL PROTEIN; GLUCOSE TRANSPORTER; HYPOXIA INDUCIBLE FACTOR 1; NICOTINAMIDE; PIMONIDAZOLE;

CONFERENCE PAPER; HUMAN; HYPOXIA; NONHUMAN; OXYGEN ELECTRODE; OXYGENATION; PRIORITY JOURNAL; TUMOR;

ANOXIA; ANTIGENS, NEOPLASM; BIOLOGICAL MARKERS; CARBONIC ANHYDRASES; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; NEOPLASMS; NITROIMIDAZOLES; OXYGEN;

EID: 33646872450     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: None     Document Type: Conference Paper

References (48)

1. L. Webster, R. J. Hodgkiss, and G. D. Wilson, Cell cycle distribution of hypoxia and progression of hypoxic tumour cells in vivo, Br. J. Cancer 77, 227-234 (1998).
2. R. E. Durand, and J. A. Raleigh, Identification of nonproliferating but viable hypoxic tumour cells in vivo, Cancer Res. 58, 3547-3550 (1998).
3. B. A. Teicher, Hypoxia and drug resistance, Cancer Metastasis Rev. 13, 39-68 (1994).
4. T. G. Graeber, C. Osmanian, T. Jacks, D. E. Housman, S. J. Koch, S. W. Lowe, and A. J. Giaccia, Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours, Nature 379, 88-91 (1996).
5. M. Höckel, K. Schlenger, B. Aral, M. Mitze, U. Schaffer, and P. Vaupel, Association between tumour hypoxia and malignant progression in advanced cancer of the uterine cervix, Cancer Res. 56, 4509-4515 (1996).
6. R. H. Thomlinson, and L. H. Gray, The histological structure of some human lung cancers and the possible implications for radiotherapy, Br. J. Cancer 9, 539-549 (1955).
7. L. H. Gray, A. D. Conger, M. Ebert, S. Hornsey, and O. C. Scott, Concentration of oxygen dissolved in tissue at the time of irradiation as a factor in radiotherapy, Br. J. Radiol. 26, 638-648 (1953).
8. P. Okunieff, M. Höckel, E. P. Dunphy, K. Schlenger, C. Knoop, and P. Vaupel, Oxygen tension distributions are sufficient to explain the local response of human breast tumours treated with radiation alone, Int. J. Radiat. Oncol. Biol. Phys. 26, 631-636 (1993).
9. 2 predicts survival in advanced cancer of the uterine cervix, Radiother. Oncol. 26, 45-50 (1993).
10. A. W. Fyles, M. Milosevic, R. Wong, M. C. Kavanagh, M. Pintilie, A. Sun, W. Chapman, W. Levin, L. Manchul, T. J. Keane, and R. P. Hill, Oxygenation predicts radiation response in patients with cervix cancer, Radiother. Oncol. 48, 149-156 (1998).
11. M. Nordsmark, and J. Overgaard, A confirmatory prognostic study on oxygenation status and regional control in advanced head and neck squamous cell carcinoma treated by radiation therapy, Radiother. Oncol. 57, 39-43 (2000).
12. D. M. Brizel, S. P. Scully, J. M. Harrelson, L. J. Layfield, J. M. Bean, L. R. Prosnitz, and M. W. Dewhirst, Tumour oxygenation predicts for the likelihood of distant metastasis in human soft tissue sarcoma, Cancer Res. 56, 941-943 (1996).
13. R. A. Gatenby, H. B. Kessler, J. S. Rosenblum, L. R. Coia, P. J. Moldofsky, W. H. Hartz, and G. J. Broder, Oxygen distribution in squamous cell carcinoma metastases and its relationship to outcome of radiation therapy, Int. J. Radiat. Oncol. Biol. Phys. 14, 831-838 (1988).
14. M. Höckel, K. Schlenger, S. Höckel, and P. Vaupel, Hypoxic cervical cancers with low apoptotic index are highly aggressive, Cancer Res. 59, 4525-4528 (1999).
15. J. Bussink, J. H. A. M. Kaanders, A. M. Strik, and A. J. van der Kogel, Effects of nicotinamide and carbogen on oxygenation in human tumour xenografts measured with luminescence based fibre optic probes, Radiother. Oncol. 57, 21-30 (2000).
16. B. M. Seddon, D. J. Honess, B. Vojnovic, G. M. Tozer, and P. Workman, Measurement of tumour oxygenation: In vivo comparison of a luminescence fibre optic sensor and a polarographic electrode in the p22 tumour, Radiat. Res. 155, 837-846 (2001).
17. J. A. Raleigh, D. P. Calkin-Adams, L. H. Rinker, C. A. Ballenger, M. C. Weissler, W. C. Fowler, D. B. Novotny, and M. A. Varia, Hypoxia and vascular endothelial growth factor expression in human squamous cell carcinomas using pimonidazole as a hypoxic marker, Cancer Res. 58, 3765-3768 (1998).
18. S. M. Evans, S. Hahn, D. R. Pook, W. T. Jenkins, A. A. Chalian, P. Zhang, C. Stevens, R. Weber, G. Weinstein, I. Benjamin, N. Mirza, M. Morgan, S. Rubin, W. G. McKenna, E. M. Lord, and C. J. Koch, Detection of hypoxia in human squamous cell carcinoma by EF5 binding, Cancer Res. 60, 2018-2024 (2000).
19. J. A. Raleigh, S. C. Chou, G. E. Arteel, and M. R. Horsman, Comparisons among pimonidazole binding, oxygen electrode measurements, and radiation response in C3H mouse tumours, Radiat. Res. 151, 580-589 (1999).
20. P. L. Olive, R. E. Durand, J. A. Raleigh, C. Luo, and C. Aquino-Parsons, Comparison between the comet assay and pimonidazole binding for measuring tumour hypoxia, Br. J. Cancer 83, 1525-1531 (2000).
21. M. Nordsmark, J. Loncaster, C. Aquino-Parsons, S. C. Chou, M. Ladekarl, H. Havsteen, J. C. Lindegaard, S. E. Davidson, M. Varia, C. West, R. Hunter, J. Overgaard, and J. A. Raleigh, Measurements of hypoxia using pimonidazole and polarographic oxygen-sensitive electrodes in human cervix carcinomas, Radiother. Oncol. 67, 35-44 (2003).
22. H. L. Janssen, F. J. Hoebers, D. Sprong, L. Goethals, K. J. Williams, I. J. Stratford, K. M. Haustermans, A. J. Balm, and A. C. Begg, Differentiation-associated staining with anti-pimonidazole antibodies in head and neck tumours, Radiother. Oncol. 70, 91-97 (2004).
23. J. H. A. M. Kaanders, K. I. E. M. Wijffels, H. A. M. Marres, A. S. E. Ljungkvist, L. A. M. Pop, F. J. A. van den Hoogen, P. C. M. de Wilde, J. Bussink, J. A. Raleigh, and A. J. van der Kogel, Pimonidazole binding and tumour vascularity predict for treatment outcome in head and neck cancer, Cancer Res. 62, 7066-7074 (2002).
24. C. W. Pugh, and P. J. Ratcliffe, The von Hippel-Lindau tumour suppressor, hypoxia-inducible factor-1 (HIF-1) degradation and cancer pathogenesis, Semin. Cancer Biol. 13, 83-89 (2003).
25. C. P. S. Potter, and A. L. Harris, Diagnostic, prognostic and therapeutic implications of carbonic anhydrases in cancer, Br. J. Cancer 89, 2-7 (2003).
26. R. S. Haber, A. Rathan, K. R. Weiser, A. Pritsker, S. H. Itzkowitz, C. Bodian, G. Slater, A. Weiss, and D. E. Burnstein, Glut-1 glucose transporter expression in colorectal carcinoma, Cancer 83, 34-40 (1998).
27. M. Younes, R. W. Brown, M. Stephenson, M. Gondo, and P. T. Cagle, Overexpression of Glut-1 and Glut-3 in stage 1 non small cell lung carcinoma is associated with poor survival, Cancer 80, 1046-1051 (1997).
28. C. C. Wycoff, N. J. P. Beasley, P. H. Watson, K. J. Turner, J. Pastorek, A. Sibtain, G. D. Wilson, H. Turley, K. L. Talks, P. H. Maxwell, C. W. Pugh, P. J. Ratcliffe, and A. L. Harris, Hypoxia-inducible expression of tumour associated carbonic anhydrases, Cancer Res. 60, 7075-7083 (2000).
29. B. L. Ebert, J. D. Firth, and P. J. Ratcliffe, Hypoxia and mitochondrial inhibitors regulate expression of glucose transporters via distinct cis-acting sequences, J. Biol. Chem. 270, 29083-29089 (1995).
30. K. J. Williams, B. A. Telfer, R. E. Airley, H. P. Peters, M. R. Sheridan, A. J. van der Kogel, A. L. Harris, and I. J. Stratford, A protective role for HIF-1 in response to redox manipulation and glucose deprivation: implications for tumourigenesis, Oncogene 21, 282-290 (2002).
31. J. A. Loncaster, A. L. Harris, S. E. Davidson, J. P. Logue, R. D. Hunter, C. C. Wycoff, J. Pastorek, P. J. Ratcliffe, I. J. Stratford, and C. M. L. West, Carbonic anhydrase (CAIX) expression, a potential new intrinsic marker of hypoxia: correlations with tumour oxygen measurements and prognosis in locally advanced carcinoma of the cervix, Cancer Res. 61, 6394-6399 (2001).
32. R. Airley, J. Loncaster, S. Davidson, M. Bromley, S. Roberts, A. Patterson, R. Hunter, I. Stratford, and C. West, Glucose transporter Glut-1 expression correlates with tumour hypoxia and predicts metastasis free survival in advanced carcinoma of the cervix, Clin. Cancer Res. 7, 928-934 (2001).
33. R. Airley, J. Loncaster, J. Raleigh, A. L. Harris, S. E. Davidson, R. D. Hunter, C. M. L. West, and I. J. Stratford, Glut-1 and CAIX as intrinsic markers of hypoxia in carcinoma of the cervix: relationship to pimonidazole binding, Int. J. Cancer 104, 85-91 (2003).
34. K. Wilbur, and N. Anderson, Electrometric and colorimetric determination of carbonic anhydrase, J. Biol. Chem. 176, 147-154 (1948).
35. S. Kaluz, M. Kaluzova, and E. Stanbridge, Expression of the hypoxia marker carbonic anhydrase IX is critically dependent on SP1 activity. Identification of a novel type of hypoxia-responsive enhancer, Cancer Res. 63, 917-922 (2003).
36. M. Cho, H. Uemura, S-C. Kim, Y. Kawada, K. Yoshida, Y. Hirao, N. Konishi, S. Saga, and K. Yoshikawa, Hypomethylation of the MN/CA9 promoter and upregulated MN/CA9 expression in human renal cell carcinoma, Br. J. Cancer 85, 563-567 (2001).
37. H. Zhong, A. M. De Marzo, E. Laughner, M. Lim, D. A. Hilton, D. Zagzag, P. Buechler, W. B. Isaacs, G. L. Semenza, and J. W. Simons, Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases, Cancer Res. 59, 5830-5835 (1999).
38. B. Bachtiary, M. Schindl, R. Potter, B. Dreier, T. H. Knocke, J. A. Hainfellner, R. Horvat, and P. Birner, Overexpression of hypoxia inducible factor 1α indicates diminished response to radiotherapy and unfavourable prognosis in patients receiving radical radiotherapy for cervical cancer, Clin. Cancer Res. 9, 2234-2240 (2003).
39. P. Burri, V. Djonov, D. Aebersold, K. Lindel, U. Studer, H. J. Altermatt, L. Mazzucchelli, R. H. Greiner, and G. Gruber, Significant correlation of hypoxia inducible factor 1α with treatment outcome in cervical cancer treated with radical radiotherapy, Int. J. Radiat. Oncol. Biol. Phys. 56, 494-501 (2003).
40. D. M. Aebersold, P. Burri, K. T. Beer, J. Laissue, V. Djonov, R. H. Greiner, and G. L. Semenza, Expression of hypoxia inducible factor 1α: a novel predictive and prognostic parameter in the radiotherapy of oropharyngeal cancer, Cancer Res. 61, 2911-2916 (2001).
41. D. Vordermark, and J. M. Brown, Evaluation of hypoxia inducible factor 1α (HIF-1α) as an intrinsic marker of tumour hypoxia in U87 MG human glioblastoma: in vitro and xenograft studies, Int. J. Radiat. Oncol. Biol. Phys. 56, 1184-1193 (2003).
42. V. Vukovic, H. K. Haugland, T. Nicklee, A. J. Morrison, and D. W. Hedley, Hypoxia inducible factor 1α is an intrinsic marker for hypoxia in cervical cancer xenografts, Cancer Res. 61, 7394-7398 (2001).
43. H. K. Haugland, V. Vukovic, M. Pintilie, A. W. Fyles, M. Milosevic, R. P. Hill, and D. W. Hedley, Expression of hypoxia inducible factor lain cervical carcinomas: correlation with tumour oxygenation, Int. J. Radiat. Oncol. Biol. Phys. 53, 854-861 (2002).
44. H. L. K. Janssen, K. M. G. Haustermans, D. Sprong, G. Blommestijn, I. Hofland, F. J. Hoebers, E. Blijweert, J. A. Raleigh, G. L. Semenza, M. A. Varia, A. J. Balm, M-L. F. van Velthuysen, P. Delaere, R. Sciot, and A. C. Begg, HIF-1A, pimonidazole and iododeoxyuridine to estimate hypoxia and perfusion in human head and neck tumors, Int. J. Radiat. Oncol. Biol. Phys. 54, 1537-1549 (2002).
45. P. H. Maxwell, M. S. Wiesener, G-W. Chang, S. C. Clifford, E. C. Vaux, M. E. Cockman, C. C. Wycoff, C. W. Pugh, E. R. Maher, and P. J. Ratcliffe, The tumour suppressor protein VHL targets hypoxia inducible factors for oxygen-dependent proteolysis, Nature 399, 271-275 (1999).
46. E. Laughner, P. Taghavi, K. Chiles, P. C. Mahon, and G. L. Semenza, HER2 (neu) signaling increases the rate of hypoxia-inducible factor 1alpha (HIF-1alpha) synthesis: novel mechanism for HIF-1-mediated vascular endothelial growth factor expression, Mol. Cell Biol. 21, 3995-4004 (2001).
47. D. Lando, J. J. Gorman, M. L. Whitelaw, and D. J. Peet, Oxygen-dependent regulation of hypoxia-inducible factors by prolyl and asparaginyl hydroxylation, Eur. J. Biochem. 270, 781-790 (2003).
48. M. Ema, K. Hirota, J. Mimura, H. Abe, J. Yodoi, K. Sogawa, L. Poellinger, and Y. Fujii-Kuriyama, Molecular mechanisms of transcription activation by HLF and HIF1alpha in response to hypoxia: their stabilization and redox signal-induced interaction with CBP/p300, EMBO J. 18, 1905-1914 (1999).